Join the Cabometyx group to help and get support from people like you.
Cabometyx News
Cabozantinib Promising for Metastatic Pheochromocytomas, Paragangliomas
MONDAY, April 29, 2024 – For patients with metastatic pheochromocytomas and paragangliomas (MPPGs), an antiangiogenic multi-tyrosine kinase inhibitor, cabozantinib, is promising, according to a...
Cabozantinib Promising for Advanced Adrenocortical Carcinoma
FRIDAY, April 26, 2024 – For patients with advanced adrenocortical carcinoma, cabozantinib shows promising efficacy, according to a study published online April 9 in The Lancet Oncology. Matthew T....
American Society of Clinical Oncology, June 2-6
The annual meeting of the American Society of Clinical Oncology was held from June 2 to 6 in Chicago and attracted more than 34,000 participants from around the world, including clinicians,...
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
FRIDAY, June 9, 2023 – For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor treatment, the addition of atezolizumab...
Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
THURSDAY, May 11, 2023 – Cabozantinib plus nivolumab and ipilimumab yields significantly longer progression-free survival than treatment with cabozantinib plus nivolumab alone among patients with...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 17, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx® (cabozantinib) for the treatment ...
FDA Approves Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) January 22, 2021-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 14, 2019-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for patients...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 19, 2017-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets...
Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 25, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib)...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Cancer